Please assess the completion status of the following clinical trial:

Trial Title: Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients are included in the study if all of the following criteria are met:~1. Written informed consent is obtained.~2. The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive).~3. The patient has a complaint of excessive sleepiness despite nCPAP therapy being effective and being a regular user of nCPAP therapy.~4. The patient has a current diagnosis of OSAHS according to International Classification of Sleep Disorders (ICSD) criteria.~5. The patient meets the following nCPAP therapy requirements:~   * Adequate education and intervention efforts to encourage nCPAP therapy use must be documented.~  * A patient's nCPAP therapy regimen must be stable for at least 4 weeks.~  * nCPAP therapy is shown to be effective, with effectiveness defined as having an apnea-hypopnea index (AHI) of 10 or less during nocturnal PSG, and, in the opinion of the investigator, nCPAP is effective therapy.~  * Following demonstration of effectiveness, evidence of regular nCPAP usage must be shown during a 2-week evaluation period (ie, nCPAP usage for at least 4 hours/night on at least 70% of the nights).~6. The patient is in good health as determined by a medical and psychiatric history, physical examination, ECG, and serum chemistry and hematology.~7. Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive \[oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method\], or intrauterine device \[IUD\]) and agree to continued use of this method for the duration of the study.~8. The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more.~9. The patient has an ESS score of 10 or more.~10. The patient does not have any medical or psychiatric disorders that could account for the excessive sleepiness.~11. The patient is able to complete self rating scales and computer-based testing.~12. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.~Exclusion Criteria:~Patients are excluded from participating in this study if 1 or more of the following criteria are met:~1. has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)~2. has a probable diagnosis of a current sleep disorder other than OSAHS~3. consumes caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day~4. used any prescription drugs disallowed by the protocol or clinically significant use of over the-counter (OTC) drugs within 7 days before the second screening visit~5. has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)~6. has a positive urine drug screen (UDS)~7. has a clinically significant deviation from normal in the physical examination~8. is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)~9. has used an investigational drug within 1 month before the initial screening visit~10. has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)~11. has a known clinically significant drug sensitivity to stimulants or modafinil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Armodafinil 250 mg/day
- 2 (Type: EXPERIMENTAL): Armodafinil 150 mg/day
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).